Characterization of the kinase domain of the ephrin-B3 receptor tyrosine kinase using a scintillation proximity assay

被引:3
作者
Bembenek, ME [1 ]
Schmidt, S [1 ]
Li, P [1 ]
Morawiak, J [1 ]
Prack, A [1 ]
Jain, S [1 ]
Roy, R [1 ]
Parsons, T [1 ]
Chee, L [1 ]
机构
[1] Millennium Pharmaceut Inc, Cambridge, MA 02139 USA
关键词
D O I
10.1089/154065803322302817
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
We have characterized a recombinantly expressed N-terminally tagged GST fusion of the tyrosine kinase domain of human EphB3. The EphB3 kinase domain was shown to phosphorylate a group of synthetic tyrosine-containing peptides derived from a proprietary biotinylated kinase-biased peptide substrate library. In addition, the enzyme activity was stimulated by the divalent cation, manganese, and inhibited by addition of magnesium. The most active tyrosine-containing peptide, a biotinylated 49-mer, displayed saturation kinetics with an apparent K-m of similar to0.4 muM. The apparent K-m for ATP was determined to be similar to3 muM. The kinetics of the reaction was linear from concentrations of enzyme of 0.5 to 2 nM, and at or below the K-m concentrations of the two substrates for at least 2 It at room temperature. Moreover, the tryrosine kinase inhibitor, PP2, produced an IC50 of roughly 0.8 muM. In addition, the enzyme tolerated the solvent DMSO and was stable to multiple freeze/thaw cycles. Stability of the enzyme at 4degreesC storage was seen out to 6 It with an similar to50% reduction of activity by 24 h. Formatting the assay in a 384-well microtiter plate produced good uniformity of signal at 100% inhibition, 50% inhibition, and no inhibition. The coefficient of variance was at or below 10% with a signal-to-background ratio of similar to24 and a z value of 0.72. Collectively, these results showed the ability to configure a robust FITS for a truncated recombinantly expressed family member of the Ephrin tyrosine kinases.
引用
收藏
页码:555 / 563
页数:9
相关论文
共 18 条
[1]   Ephs and ephrins close ranks [J].
Cutforth, T ;
Harrison, CJ .
TRENDS IN NEUROSCIENCES, 2002, 25 (07) :332-334
[2]  
FABBRO D, 2003, PHARMACOL THERAPEUT, V93, P79
[3]   Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor - Study of Lck- and FynT-dependent T cell activation [J].
Hanke, JH ;
Gardner, JP ;
Dow, RL ;
Changelian, PS ;
Brissette, WH ;
Weringer, EJ ;
Pollok, K ;
Connelly, PA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (02) :695-701
[4]   Crystal structure of the ligand-binding domain of the receptor tyrosine kinase EphB2 [J].
Himanen, JP ;
Henkemeyer, M ;
Nikolov, DB .
NATURE, 1998, 396 (6710) :486-491
[5]   Eph receptors and ephrins [J].
Himanen, JP ;
Nikolov, DB .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2003, 35 (02) :130-134
[6]   Crystal structure of an Eph receptor-ephrin complex [J].
Himanen, JP ;
Rajashankar, KR ;
Lackmann, M ;
Cowan, CA ;
Henkemeyer, M ;
Nikolov, DB .
NATURE, 2001, 414 (6866) :933-938
[7]   Eph signaling: a structural view [J].
Himanen, JP ;
Nikolov, DB .
TRENDS IN NEUROSCIENCES, 2003, 26 (01) :46-51
[8]   Bidirectional signalling through the EPH-family receptor Nuk and its transmembrane ligands [J].
Holland, SJ ;
Gale, NW ;
Mbamalu, G ;
Yancopoulos, GD ;
Henkemeyer, M ;
Pawson, T .
NATURE, 1996, 383 (6602) :722-725
[9]   Protein kinase inhibitors as a therapeutic modality [J].
Levitzki, A .
ACCOUNTS OF CHEMICAL RESEARCH, 2003, 36 (06) :462-469
[10]   Coexpression of ephrin-Bs and their receptors in colon carcinoma [J].
Liu, WB ;
Ahmad, SA ;
Jung, YD ;
Reinmuth, N ;
Fan, F ;
Bucana, CD ;
Ellis, LM .
CANCER, 2002, 94 (04) :934-939